Citigroup maintains Caris Life Sciences at Buy, raises price target to $36 from $28

Citigroup kept its Buy rating on Caris Life Sciences and increased its price target to $36 from $28, suggesting a 42.7% upside from the Nov 6 close of $25.23. Recent analyst price targets for the company range from $30 to $38.

Original reporting
Published Nov 6, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Caris Life Sciences at Buy, raises price target to $36 from $28 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst target raise suggests improved growth outlook, but market reaction may be muted due to small float.

02

Market read

Analyst upgrade provides a modest catalyst for CRIS, primarily of interest to biotech traders.

03

What to watch

Potential dilution from future financing rounds.

Relevance 5/10Novelty 4/10Timing: today

Background

Caris Life Sciences (CRIS) is a molecular diagnostics company focused on cancer testing.

Market effects

May lift sentiment in the biotech/diagnostics sector.

Limited to US biotech investors.

Low global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoint.

Key entities

  • Citigroup

    Equity research firm that issued the upgraded target.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.